Results 161 to 170 of about 123,413 (291)

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao, Changxin Zhong, Shilong Jiang, Yungui Li, Yang Xi, Mingxuan Xiao, Ting Jiang, Xiaoya Wan, Zonglin Chen, Xiaohui Yu, Yan Cheng   +10 more
wiley   +1 more source

Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case. [PDF]

J Immunother Cancer
Vallacchi V, Vergani E, Cossa M, Gargiuli C, Busico A, Devecchi A, Dugo M, Bergamaschi L, De Cecco L, Cavalieri S, Valeri B, Tamborini E, Gallino G, Del Vecchio M, Santinami M, Sensi M, Rivoltini L, Di Guardo L, Rodolfo M.   +18 more
europepmc   +1 more source

The principles of disease elimination and eradication

, 1998
Walter R. Dowdle
openalex   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

Advanced Science, EarlyView.
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély, István Narozsny, Levente Szarka, Daniel V. Veres, Peter Csermely, Dávid Keresztes   +5 more
wiley   +1 more source

Nucleoside‐Based Hydrogel Platform Synergizes with Photothermal Effects for Enhanced Biofilm Eradication Against Periodontitis

Advanced Science, EarlyView.
A synergistic antibiofilm hydrogel platform (ZBAg@FNP) is developed by encapsulating an organic small‐molecule photothermal agent (FNP) within a silver ion‐mediated supramolecular hydrogel (ZBAg), enabling photothermal disruption of biofilm integrity and controlled Ag⁺ ion release upon irradiation.
Yinghui Wen, Yunfei Li, Tiannan Liu, Chongkui Sun, Hang Zhao, Yao Yuan, Shiping Yang, Tingxing Zhao, Jiang Liu   +8 more
wiley   +1 more source

ERADICATION PROGRAM OF FOOT AND MOUTH DISEASE IN THE STATE OF SÃO PAULO: EVALUATION OF OFFICIAL DATA OBTAINED BETWEEN 1997-2012

, 2018
Acácio Romualdo Assoni Rodrigues, Luís Guilherme de Oliveira, Igor Renan Honorato Gatto, Henrique Meiroz de Souza Almeida, Gabriel Augusto Marques Rossi, Marina Lopes Mechler-Dreibi, Samir Issa Samara   +6 more
openalex   +1 more source

CLL2-BXX Phase II Trials: Sequential, Targeted Treatment for Eradication of Minimal Residual Disease in Chronic Lymphocytic Leukemia [PDF]

, 2018
Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Anja Engelke, Petra Langerbeins, Anna‐Maria Fink, Kirsten Fischer, Clemens‐Martin Wendtner, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek   +12 more
openalex   +1 more source

Nanozyme Microrobots: Programmable Spatiotemporal Catalysis for Targeted Therapy and Diagnostics

Advanced Science, EarlyView.
This review presents nanozyme microrobots as emerging catalytic systems that integrate mobility, external actuation, and adaptive reactivity to achieve precise biochemical functions. By examining mobility‐regulated catalysis, spatial targeting, integrated designs, and translational demonstrations, the article highlights how nanozyme robotics enables ...
Hong Huy Tran, Nil Kanatha Pandey, David P. Cormode, Daeyeon Lee, Edward Steager, Hyun Koo   +5 more
wiley   +1 more source